Rabbit anti-Human Menin Polyclonal Antibody | anti-MEN1 antibody

Menin (MEN1, Multiple Endocrine Neoplasia I, MEAI, SCG2, Wermer Syndrome, Zollinger Ellison Syndrome, ZES) (PE)

Cat. Num. AAA6487755

• Gene Names: MEN1; MEAI; SCG2
• Reactivity: Human
• Applications: Immunohistochemistry, Western Blot
• Purity: Purified by Protein G Affinity Chromatography.
• Synonyms: Menin; Polyclonal Antibody; Menin (MEN1; Multiple Endocrine Neoplasia I; MEAI; SCG2; Wermer Syndrome; Zollinger Ellison Syndrome; ZES) (PE); anti-MEN1 antibody

• Host: Rabbit
• Reactivity: Human
• Clonality: Polyclonal
• Isotype: IgG
• Specificity: Recognizes human MEN1.
• Purity/Purification: Purified by Protein G Affinity Chromatography.
• Form/Format: Supplied as a liquid in PBS, pH 7.2. No preservative added. Labeled with R-Phycoerythrin (PE).

• Applicable Applications for anti-MEN1 antibody: Immunohistochemistry (IHC), FLISA, Western Blot (WB)
• Application Notes: IHC: 1:10-1:50; FLISA: 1:1,000; WB: 1:50-1:100; Applications are based on unconjugated antibody.
• Immunogen: Synthetic peptide corresponding to amino acid residues surrounding T594 of human MEN1 (KLH).
• Conjugate: PE
• Note: Preservative Free
• Special Handling: Light sensitive
• Preparation and Storage: Store product at 4 degree C in the dark. DO NOT FREEZE! Stable at 4 degree C for 12 months after receipt as an undiluted liquid. Dilute required amount only prior to immediate use. Further dilutions can be made in assay buffer. Caution: PE conjugates are sensitive to light. For maximum recovery of product, centrifuge the original vial prior to removing the cap.

Western Blot (WB)

(Western blot analysis of anti-MEN1 Antibody (T594) in Ramos cell line lysates (35ug/lane). MEN1(arrow) was detected using the purified Pab.)

Immunohistochemistry (IHC)

(Formalin-fixed and paraffin-embedded human prostata carcinoma tissue reacted with MEN1 Antibody (T594), which was peroxidase-conjugated to the secondary antibody, followed by DAB staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated.)

Immunofluorescence (IF)

(Confocal immunofluorescent analysis of MEN1 Antibody (T594) with Hela cell followed by Alexa Fluor 488-conjugated goat anti-rabbit lgG (green).DAPI was used to stain the cell nuclear (blue).)

Product Categories/Family for anti-MEN1 antibody

Antibodies; Disease Markers

References

1. Hashimoto, M., Int. J. Oncol. 33(2), 333-340 (2008). 2. Vidal, A., J Eur Acad Dermatol Venereol 22(7), 835-838 (2008). 3. Pieterman, C.R., Clin. Endocrinol. (Oxf) (2008).

NCBI and Uniprot Product Information

• NCBI GI #: 18860839
• NCBI GeneID: 4221
• NCBI Accession #: NP_000235
• NCBI GenBank Nucleotide #: NM_000244
• UniProt Accession #: O00255
• Molecular Weight: 16,146 Da
• NCBI Official Full Name: menin isoform 1
• NCBI Official Synonym Full Names: multiple endocrine neoplasia I
• NCBI Official Symbol: MEN1
• NCBI Official Synonym Symbols: MEAI; SCG2
• NCBI Protein Information: menin
• UniProt Protein Name: Menin
• Protein Family: Menin
• UniProt Gene Name: MEN1
• UniProt Synonym Gene Names: SCG2
• UniProt Entry Name: MEN1_HUMAN

Uniprot Description

MEN1: Essential component of a MLL/SET1 histone methyltransferase (HMT) complex, a complex that specifically methylates 'Lys-4' of histone H3 (H3K4). Functions as a transcriptional regulator. Binds to the TERT promoter and represses telomerase expression. Plays a role in TGFB1-mediated inhibition of cell-proliferation, possibly regulating SMAD3 transcriptional activity. Represses JUND-mediated transcriptional activation on AP1 sites, as well as that mediated by NFKB subunit RELA. Positively regulates HOXC8 and HOXC6 gene expression. May be involved in normal hematopoiesis through the activation of HOXA9 expression. May be involved in DNA repair. Component of MLL-containing complexes (named MLL, ASCOM, MLL2/MLL3 or MLL3/MLL4 complex): at least composed ASH2L, RBBP5, DPY30, WDR5, one or several histone methyltransferases (MLL, MLL2, MLL3 and/or MLL4), and the facultative components MEN1, HCFC1, HCFC2, NCOA6, KDM6A, PAXIP1/PTIP and C16orf53/PA1. Interacts with POLR2A phosphorylated at 'Ser-5', but not with the unphosphorylated, nor 'Ser-2' phosphorylated POLR2A forms. Interacts with FANCD2 and DBF4. Interacts with JUND. Interacts with SMAD3, but not with SMAD2, nor SMAD4. Directly interacts with NFKB1, NFKB2 and RELA. Ubiquitous. 3 isoforms of the human protein are produced by alternative splicing.

Protein type: Transcription, coactivator/corepressor

Chromosomal Location of Human Ortholog: 11q13

Cellular Component: nucleoplasm; histone methyltransferase complex; protein complex; nuclear matrix; cytoplasm; cytosol; nucleus; chromatin; cleavage furrow

Molecular Function: protein binding, bridging; Y-form DNA binding; protein binding; four-way junction DNA binding; sequence-specific DNA binding; double-stranded DNA binding; protein N-terminus binding; chromatin binding; histone-lysine N-methyltransferase activity

Biological Process: negative regulation of JNK cascade; maternal process involved in pregnancy; positive regulation of protein binding; positive regulation of caspase activity; palate development; negative regulation of transcription from RNA polymerase II promoter; negative regulation of cell cycle; negative regulation of cell proliferation; negative regulation of protein amino acid phosphorylation; transforming growth factor beta receptor signaling pathway; response to gamma radiation; negative regulation of osteoblast differentiation; hemopoiesis; cell cycle arrest; response to UV; leukocyte homeostasis; transcription initiation from RNA polymerase II promoter; positive regulation of histone methylation; transcription, DNA-dependent; negative regulation of transcription factor activity; positive regulation of transforming growth factor beta receptor signaling pathway; MAPKKK cascade; negative regulation of cyclin-dependent protein kinase activity; negative regulation of organ growth; DNA repair; regulation of activin receptor signaling pathway; osteoblast development; embryonic skeletal morphogenesis; chromatin remodeling; negative regulation of telomerase activity; positive regulation of osteoblast differentiation; positive regulation of cell division; positive regulation of transcription from RNA polymerase II promoter; gene expression; brain development; negative regulation of transcription, DNA-dependent; response to DNA damage stimulus; osteoblast fate commitment

Disease: Multiple Endocrine Neoplasia, Type I